Cambridge, United States
Immuneering Corporation, founded in 2008, is a pioneering biopharmaceutical company headquartered in the United States. Specializing in Biotechnology and Pharmaceuticals, Immuneering's slogan, “Better Medicines Through Signaling Dynamics,” reflects its commitment to enhancing patient outcomes in cancer and neurological diseases.
Immuneering leverages over a decade of expertise in translational bioinformatics, a unique asset that informs its drug development strategy. The company has developed a versatile platform capable of converting human data, innovative biology, and chemistry into meaningful therapeutic advances. This framework underpins its extensive and varied drug pipeline, with significant implications for oncology.
The company's lead product candidate, IMM-1-104, is a highly selective dual-MEK inhibitor designed to target advanced solid tumors with RAS mutations. Beyond this, Immuneering is advancing six preclinical oncology programs targeting the MAPK and mTOR pathways, and two neuroscience programs.
In its latest financial move, Immuneering secured a $30.00M Post-IPO Equity investment as of 01 April 2023, further reinforcing its capacity to drive innovation in drug development.
Sompharmaceuticals
